Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug
Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
September 9, 2020Inside Waisman: Meet Lindsay McCary
As a third year graduate student in school psychology at the University of South Carolina, Lindsay McCary, PhD, was looking for a new advisor to help her with her dissertation. At the time, Jane Roberts, PhD, had just joined the Department of Psychology and had some data available on younger children with the genetic disorder fragile X syndrome (FXS). McCary was immediately fascinated by the new professor’s research because it integrated both behavioral and physiological data to examine an individual’s observable characteristics.
September 9, 2020Friends present staff, students and family awards
The Friends of the Waisman hosts this annual event for members of the Friends organization; community supporters of the Waisman Center; and Waisman Center faculty, staff, and students. The 2020 Awards were presented at a virtual meeting on August 18 2020.
September 4, 2020Running toward renewal: new study links physical activity with cognitive health
Research has shown voluntary running is an activity most commonly associated with the reversal of negative impacts of aging and neurodegeneration, but little is understood about why that is.
August 4, 2020UW researchers devise approach to treat rare, incurable form of blindness
Waisman Center investigator David Gamm, MD, PhD, and Waisman affiliate Kris Saha, PhD, have published a proof-of-concept method to correct Best disease – an inherited form of macular degeneration that causes blindness, and that is …
August 3, 2020Waisman Biomanufacturing partners with Heat Biologics to manufacture COVID-19 vaccine
Waisman Biomanufacturing at the University of Wisconsin–Madison is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and phase 2 clinical trials. Phase 1 trials could begin in early 2021 and UW–Madison may be a trial site.
August 3, 2020The ECHO Effect
Project ECHO (the mantra for which is “All teach, all learn”) uses video-conferencing technology to provide education and case consultation on best practice clinical services, training, and resources for individuals with specific healthcare needs that are difficult to meet locally. The Waisman Center ECHO platform will serve as a diagnostic and treatment training hub to share the center’s expertise on intellectual and developmental disabilities, such as autism, Down syndrome, and cerebral palsy, throughout the state and beyond.
July 28, 2020Research Core Revitalization Program funds upgrades to shared resources on campus
Projects from three research cores at the Waisman Center are among 17 UW core projects to receive grants from the Research Core Revitalization Program—an initiative with support from the Office of the Vice Chancellor for …
July 23, 2020Balancing act: what motor function can tell us about autism
Can the way a person moves be a key identifier of autism? It’s a question that Waisman Center investigator Brittany Travers, PhD, is trying to answer. A new paper from Travers’ lab suggests that movement patterns of individuals with autism spectrum disorder (ASD) may differ from those with typical development.
June 15, 2020
Serving During COVID-19: AAC Outreach Services
The Communication Development Program (CDP) is an outreach program of the Waisman Center UCEDD at University of Wisconsin, Madison. This program was developed over 30 years ago in partnership with the Dane County Department of …
May 12, 2020The Social Brain: A Beautiful Mind
What images come to mind when you hear the phrase social brain? Do you think of children running around on a playground laughing together? Do you think of problem solving or imagine colorful brain scans? Do you think of autism? These are the questions that inspired a breadth of autism research that was recently evaluated by a team of Waisman scientists and compiled into a new literature review.
May 6, 2020Grant awarded for eye disease research
A big congratulations to researcher Kim Edwards and Waisman investigator David Gamm, MD, PhD, on winning the inaugural Randy Wheelock Research Award. Gamm is also an associate professor of ophthalmology and visual science as well as the director of the McPherson Eye Research Institute.
May 6, 2020Waisman Teacher Recognized with Staff Excellence Award
Academic staff members bring UW–Madison’s mission to life — they are gifted teachers, world-class researchers and dedicated administrators. None of that has changed with COVID-19. If anything, their creativity and dedication is more needed and …
April 28, 2020
Spurred by COVID-19 pandemic, telehealth becomes mainstream at Madison clinics, hospitals
“It was awesome. It saves us from having to take time off work and having to travel,” said Nicole Gantz, whose 8-year-old son Joshua has Down syndrome and an attention disorder. Nicole and Joshua visited with Maria Stanley, a …
April 27, 2020Seth Pollak elected to American Academy of Arts and Sciences
Six University of Wisconsin–Madison faculty have been elected to the American Academy of Arts and Sciences, including Waisman Center investigator and psychologist Seth Pollak, PhD. Pollak is the College of Letters & Science Distinguished Professor …
April 27, 2020For Caregivers Of Children With Autism, COVID-19 Conditions Can Present Extra Challenges
It’s hard to think of an aspect of life that hasn't changed since the novel coronavirus began spreading across the globe. Many aspects of life — from work, to school, to travel, shopping and socializing — are dramatically different than they were just a few months ago.
April 13, 2020School closure strains families with children who have disabilities
Waisman investigator Sigan Hartley, PhD, was recently featured in a Wisconsin State Journal article about the difficulties being faced by children with special needs and their families while schools are currently shut down. This article …
April 10, 2020UW–Madison’s EdNeuroLab tackling math learning through brain imaging
In 2012, Edward Hubbard, a cognitive neuroscientist and assistant professor with UW‒Madison’s Department of Educational Psychology, created the Educational Neuroscience Lab to understand — through functional magnetic resonance imaging (fMRI) — how the physical changes that occur in children’s brains as they learn may help improve education practices.
April 9, 2020
Improved technique illuminates fragile X protein
Researchers at the Waisman Center made a significant step in understanding the function of a specific protein, FMR1, whose absence causes fragile X syndrome, or FXS. Waisman investigators Xinyu Zhao, PhD, and Anita Bhattacharyya, PhD, with research associate Meng Li, published their paper “Identification of FMR1-regulated molecular networks in human neurodevelopment” in the March issue of the journal Genome Research.
April 9, 2020
Task force offers tools allowing patients on ventilators to communicate
For a patient suffering from a life-threatening illness like COVID-19, communication means everything. If that person is on a ventilator and no visitors are allowed in the room, doctors and nurses must rely on tools …
April 2, 2020Five language outcome measures evaluated for intellectual disabilities studies
A multi-university team of researchers found that expressive language sampling (ELS) can be useful in measuring outcomes in clinical trials targeting fragile X syndrome (FXS). According to their study, ELS, a set of procedures for collecting and analyzing spoken language in natural verbal interactions, yielded five language-related outcome measures that may be useful for treatment studies in intellectual disabilities, especially FXS.
March 25, 2020
Thoughts of Gratitude: Scott Kornstedt
Shortly after Raegan was born to Scott and his wife Carrie, she was diagnosed with phenylketonuria, or PKU — a rare metabolic disorder that prevents her from properly metabolizing phenylalanine, a common amino acid that exists in most proteins. PKU is a rare disorder that affects approximately 16,000 people in the U.S. It is one of 47 disorders for which newborns in Wisconsin are screened. If left untreated, it can cause intellectual disabilities, seizures, among other health-related issues.
March 16, 2020- More News posts
Advancing knowledge of human development, developmental disabilities, and neurodegenerative diseases.